Early and Accurate Diagnosis of Melanoma is Critical for Long-Term Survival.1

What is myPath® Melanoma?

Myriad Genetic Laboratories has developed myPath® Melanoma, a clinically validated test to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone. Reasons that definitive diagnosis may not be achievable by histopathology include indeterminate or ambiguous histopathologic features, diagnostic disagreement among physicians, or indications that additional workup or consultation are necessary.

The test measures the expression of 23 genes by qRT-PCR methodology and distinguishes melanoma from nevi with a sensitivity of 90-94% and a specificity of 91-96%. 7,29,30

90% - 94%

Sensitivity

91% - 96%

Specificity

Watch Dr. Loren Clarke
answer questions about
myPath Melanoma

Watch and Learn

Testing Process

In light of the public health preparedness efforts currently underway, Myriad’s top priorities are protecting the health and safety of employees, our customers, and their patients.

Click here to learn more about our measures to help keep you and your patients safe.

How the myPath Melanoma Test Works

The myPath Melanoma test measures 23 genes for which expression patterns differ between malignant melanoma and benign nevi. These genes are involved in cell differentiation, cell signaling, and immune response signaling.

Covered by Medicare

9 out of 10 patients pay $0

The estimated average out-of-pocket cost

after insurance and financial assistance

Subscribe To Our Email Updates

“Melanocytic lesions continue to pose significant interpretive problems to histopathologists.”

Lorenzo Cerroni, et al

Myriad Corporate Headquarters

(800) 231-4442

320 Wakara Way

Salt Lake City, UT 84108

mypathCS@myriad.com

References     Contact     Notice of Privacy Practices     Terms of Use    Privacy Policy

Copyright © 2019 Myriad myPath Melanoma. All rights reserved.